Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0YC4F
|
||||
| Former ID |
DIB005426
|
||||
| Drug Name |
K-828-AB
|
||||
| Synonyms |
GABA transaminase inhibitor (oral, dementia), Kowa
|
||||
| Indication | Dementia [ICD9: 290-294; ICD10:F01-F07] | Phase 2 | [1] | ||
| Company |
Kowa Co Ltd
|
||||
| Target and Pathway | |||||
| Target(s) | 4-aminobutyrate aminotransferase, mitochondrial | Target Info | Inhibitor | [2] | |
| BioCyc Pathway | GABA shunt | ||||
| Valine degradation | |||||
| Beta-alanine degradation | |||||
| 4-aminobutyrate degradation | |||||
| KEGG Pathway | Alanine, aspartate and glutamate metabolism | ||||
| Valine, leucine and isoleucine degradation | |||||
| beta-Alanine metabolism | |||||
| Propanoate metabolism | |||||
| Butanoate metabolism | |||||
| Metabolic pathways | |||||
| GABAergic synapse | |||||
| PANTHER Pathway | Aminobutyrate degradation | ||||
| Pyrimidine Metabolism | |||||
| Gamma-aminobutyric acid synthesis | |||||
| PathWhiz Pathway | Aspartate Metabolism | ||||
| Glutamate Metabolism | |||||
| Beta-Alanine Metabolism | |||||
| Valine, Leucine and Isoleucine Degradation | |||||
| Propanoate Metabolism | |||||
| WikiPathways | GABA synthesis, release, reuptake and degradation | ||||
| Alanine and aspartate metabolism | |||||
| References | |||||
| REF 1 | Clinical pipeline report, company report or official report of Kowa Co Ltd. | ||||
| REF 2 | Phase II clinical trial of K-828-AB for treating behavioral and psychological symptoms of dementia. Kowa Co. Ltd. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.